HIV Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: September 02, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
USD 30.89 billion |
|
Revenue forecast in 2030 |
USD 53.08 billion |
|
Growth Rate |
CAGR of 6.2% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Segments covered |
Drug Class, Distribution Channel |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global HIV drugs market was pegged at US$ 30.89 billion in 2021 and is expected to register a revenue CAGR of 6.2% during the forecast period.
Market Fundamentals
One of the fatal chronic viral diseases and an incurable virus is HIV, also known as the Human Immunodeficiency Virus infection. It attacks the immune system of an individual and makes the body dispose of various infections and other diseases. The HIV virus can spread by using contaminated needles or syringes, as well as blood, breast milk, semen, and other sources. Anti-retroviral therapy is used to treat HIV/AIDS and manage the infection. Numerous drug classes work at various points in the HIV life cycle. The usage of these drugs assists patients in maintaining a healthy immune system and guards against other opportunistic infections that could be fatal. These drugs help in preventing the multiplication of the virus and hence reducing the chances of its transmission.
[756322]
Market Dynamics
HIV infection rates are growing exponentially. The UNAIDS 2021 factsheet estimates that there are about 30 million HIV-positive individuals alive currently. As a result, sales of HIV medications ascended. As more individuals are becoming aware of the virus and the available pharmacological therapies for the same, the number of people undergoing HIV therapy is rising. The factors accelerating the market revenue growth include the launch of new HIV medications, increased clinical studies, and other R&D activities. Furthermore, increasing government efforts to educate the general population about the causes, symptoms, and pharmacological therapy are also influencing the market revenue growth. However, strict drug approvals as well as the side effects associated with the consumption of few drugs, are expected to hinder the market revenue growth to some extent.
Market Ecosystem
The global market has been analyzed from three perspectives: drug class, distribution channel, and region.
HIV Drugs Market by Drug Class
[785943]
Based on drug class, the global HIV drugs market has been segmented into, non-nucleoside reverse transcriptase inhibitors (NRTIs), integrase inhibitors, and combination drugs.
The combination HIV drug segment accounts for the largest revenue share, and it is expected to maintain its dominance during the forecast period. The large revenue share of this segment can be attributed to the improving outcomes in the pharmacological treatment of HIV and co-infections and the increasing demand for this drug class.
In 2021, the integrase inhibitors segment accounted for the second-largest revenue share and it is expected to register significant revenue growth during the forecast period. The International AIDS Society recommends integrase inhibitors as the initial pharmacological therapy for new human immunodeficiency virus infections (IAS).
HIV Drugs Market by Distribution Channel
Based on the distribution channel, the global HIV drugs market has been segmented into, online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies segment dominates the HIV drugs market because of the large patient footfall in the hospital for the treatment of HIV. Additionally, an increase in anti-retroviral drug prescriptions is expected to support revenue growth during the forecast period.
HIV Drugs Market by Region
Based on the region, the global HIV drugs market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America accounts for the largest revenue share in the global HIV drugs market and it is expected to maintain its dominance during the forecast period. The dominance of North America can be attributed to the increasing frequency of HIV infections among the U.S. population.
Europe is expected to be the second-largest revenue-generating market due to the concentration of known HIV drug manufacturers in the region. Additionally, increasing partnerships and collaborations between market participants to expand their footprint is expected to support the market revenue growth during the forecast period.
On the other hand, the Asia Pacific HIV drugs market is expected to register significant revenue growth during the forecast period because of the growing populations of China and India, and an increase in the need for HIV medications in the coming years.
Competitive Landscape
Some of the prominent players operating in the global HIV drugs market are:
Strategic Developments
The global HIV drugs market is expected to register a revenue CAGR of 6.2%.
Increased awareness amongst people to receive HIV therapy and increased government initiatives to conduct awareness programs are the major factors governing the revenue growth of the global HIV drugs market.
Merck, AbbVie, and Jassen Pharmaceuticals are among the key players operating in the market.
The combination HIV drugs segment holds the majority of the market revenue share its better efficacy in HIV management and its association with advanced technology.
Asia Pacific region is expected to register the highest revenue growth during the forecast period.
*Insights on financial permanence is subject to availability of information in public domain